Retevmo
Lilly Unveils Exciting Phase III Showdown: Retevmo vs. Keytruda & Chemotherapy in RET Fusion-Positive NSCLC
Anika Sharma
ESMO 2023: LBA4 RET fusion is found in about 1-2% of patients with non-small cell lung cancer. Retevmo, a highly ...
Eli Lilly Sets Example for Roche with Positive Retevmo Results in Thyroid Cancer, Highlighting Feasibility of Trial
Anika Sharma
Just a few weeks ago, Roche had expressed doubts about the feasibility of a Phase 3 study involving its RET ...
Lilly’s Retevmo Outperforms Gavreto in Lung Cancer Study
SG Tylor
Source – Eli Lilly In the ongoing rivalry between Eli Lilly and Blueprint Medicines over their RET inhibitors, Eli Lilly ...
